Roanna Ruiz
Stock Analyst at Leerink Partners
(0.91)
# 3,921
Out of 4,989 analysts
65
Total ratings
36.59%
Success rate
-14%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $8.00 | +12.50% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $2.77 | +152.71% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $11.24 | +60.14% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.33 | -24.81% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $5.26 | +280.23% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $9.63 | +180.37% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $5.42 | +139.85% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $6.15 | +127.64% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $438.75 | -24.79% | 1 | Feb 5, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $58 | $48.29 | +20.11% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $83.84 | -70.18% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $7.81 | +527.40% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.63 | +130.91% | 7 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $2.90 | +106.90% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $26.76 | -29.00% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $53.23 | +125.44% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $10.75 | +365.12% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.44 | +159.07% | 6 | Oct 19, 2022 |
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $8.00
Upside: +12.50%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $2.77
Upside: +152.71%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $11.24
Upside: +60.14%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.33
Upside: -24.81%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $5.26
Upside: +280.23%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.63
Upside: +180.37%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $5.42
Upside: +139.85%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $6.15
Upside: +127.64%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $438.75
Upside: -24.79%
Cytokinetics
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $48.29
Upside: +20.11%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $83.84
Upside: -70.18%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $7.81
Upside: +527.40%
Jan 27, 2023
Maintains: Outperform
Price Target: $12 → $13
Current: $5.63
Upside: +130.91%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $2.90
Upside: +106.90%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $26.76
Upside: -29.00%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $53.23
Upside: +125.44%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $10.75
Upside: +365.12%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.44
Upside: +159.07%